{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:15:34Z","timestamp":1794107734021,"version":"4.8.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Despite the benefits of early and effective glycemic control in the management of type 2 diabetes (T2D), achieving glycated hemoglobin (HbA\n                    <jats:sub>1c<\/jats:sub>\n                    ) targets is challenging in some patients. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide effective reductions in HbA\n                    <jats:sub>1c<\/jats:sub>\n                    and body weight. Semaglutide is the only GLP-1RA that is available in both an injectable and oral formulation. The efficacy of once-weekly subcutaneous semaglutide and once-daily oral semaglutide has been investigated in the global SUSTAIN and PIONEER phase III clinical trial programs in a range of clinical settings, including early T2D managed with diet and exercise only, more established T2D uncontrolled on one to three oral antidiabetic drugs, and advanced disease treated with insulin. Across the SUSTAIN program, once-weekly subcutaneous semaglutide 1.0 mg reduced HbA\n                    <jats:sub>1c<\/jats:sub>\n                    by 1.5\u20131.8% after 30\u201356 weeks, which was significantly more than sitagliptin, liraglutide, exenatide extended release, dulaglutide, canagliflozin, or insulin glargine. Across the PIONEER program, once-daily oral semaglutide 14 mg reduced HbA\n                    <jats:sub>1c<\/jats:sub>\n                    by 1.0\u20131.4%, significantly more than sitagliptin or empagliflozin, and to a similar extent as liraglutide after 26 weeks. In addition, subcutaneous semaglutide reduced body weight significantly more than all active comparators tested, while oral semaglutide reduced body weight more than sitagliptin and liraglutide, and to a similar extent as empagliflozin. Neither formulation of semaglutide has been associated with an increased risk of hypoglycemia and both improve various measures of health-related quality of life. Semaglutide offers the benefits of a highly effective GLP-1RA in both injectable and oral formulations. Selection of the most appropriate formulation can be made on an individual basis to best suit the patient\u2019s preferences and needs.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2021.645617","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T10:31:23Z","timestamp":1624617083000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":124,"title":["Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation"],"prefix":"10.3389","volume":"12","author":[{"given":"Juris J.","family":"Meier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1144","article-title":"The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study)","volume":"42","author":"Laiteerapong","year":"2019","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107607","article-title":"Time in suboptimal glycemic control over 10 years for patients newly diagnosed with type 2 diabetes","volume":"34","author":"An","year":"2020","journal-title":"J Diabetes Complicat"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018.\u00a0A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154242","article-title":"Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors","volume":"107","author":"Davies","year":"2020","journal-title":"Metabolism"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.27.2.100","article-title":"Novel agents for the treatment of type 2 diabetes","volume":"27","author":"DeFronzo","year":"2014","journal-title":"Diabetes Spectr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13300-018-0535-9","article-title":"A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes","volume":"10","author":"Romera","year":"2019","journal-title":"Diabetes Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30182-2","article-title":"Pioneering oral peptide therapy for patients with type 2 diabetes","volume":"7","author":"Nauck","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B11","unstructured":"Ozempic\u00ae Prescribing Information"},{"key":"B12","unstructured":"Ozempic\u00ae Summary of Product Characteristics"},{"key":"B13","unstructured":"Rybelsus\u00ae Prescribing Information"},{"key":"B14","unstructured":"Rybelsus\u00ae Summary of Product Characteristics"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide","author":"Smits","year":""},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety and tolerability of oral semaglutide versus placebo added to insulin \u00b1 metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645566","article-title":"Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6","author":"Nauck","year":""},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13804","article-title":"Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: the PIONEER 1 randomized clinical trial as an example","volume":"21","author":"Aroda","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13816","article-title":"Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials","volume":"21","author":"Jendle","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.05.016","article-title":"Using patient reported outcomes in diabetes research and practice: recommendations from a national workshop","volume":"153","author":"Marrero","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes","volume":"58","author":"Granhall","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B39","article-title":"Similar efficacy and gastrointestinal tolerability versus exposure for oral and subcutaneous semaglutide","author":"Overgaard","year":""},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00706-y","article-title":"Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1-2 oral antidiabetics: systematic review and network meta-analysis","volume":"10","author":"Nuhoho","year":"2019","journal-title":"Diabetes Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.05.009","article-title":"Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes","volume":"38","author":"Spain","year":"2016","journal-title":"Clin Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-014-0068-x","article-title":"Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities","volume":"7","author":"Brod","year":"2014","journal-title":"Patient"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pcd.2016.09.003","article-title":"Clinical inertia to insulin initiation and intensification in the UK: a focused literature review","volume":"11","author":"Khunti","year":"2017","journal-title":"Prim Care Diabetes"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2337\/db20-2216-PUB","article-title":"Patient preferences for newer oral therapies in type 2 diabetes","volume":"69","author":"Savarese","year":"2020","journal-title":"Diabetes"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14244","article-title":"Patients\u2019 preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study","volume":"23","author":"Boye","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01561-1","article-title":"Preference for oral and injectable GLP-1RA therapy profiles in Japanese patients with type 2 diabetes: a discrete choice experiment","volume":"38","author":"Igarashi","year":"2020","journal-title":"Adv Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1117433","article-title":"A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes","volume":"32","author":"Hauber","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S187907","article-title":"Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes","volume":"13","author":"Thieu","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"B50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12955-017-0696-7","article-title":"Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies","volume":"15","author":"Suzuki","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"B51","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/jdi.12906","article-title":"Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial","volume":"10","author":"Takase","year":"2019","journal-title":"J\u00a0Diabetes Investig"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S99732","article-title":"Adherence to\u00a0GLP-1RA therapy administered by\u00a0once-daily\u00a0or\u00a0once-weekly\u00a0injection in patients with type 2 diabetes in Germany","volume":"9","author":"Qiao","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0470-y","article-title":"Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a medicare population","volume":"34","author":"Nguyen","year":"2017","journal-title":"Adv Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12902","article-title":"Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide","volume":"19","author":"Alatorre","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B55","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s13300-018-0396-2","article-title":"Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Italy: a retrospective cohort study","volume":"9","author":"Federici","year":"2018","journal-title":"Diabetes Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/03007995.2018.1538011","article-title":"Utilization patterns of\u00a0glucagon-like peptide-1\u00a0receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study","volume":"35","author":"Otto","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"B57","unstructured":"Euthyrox Summary of Product Characteristics2017"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0630-6","article-title":"Management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide, exenatide ER, liraglutide and lixisenatide: a cost-effectiveness analysis in the Danish setting","volume":"10","author":"G\u00e6de","year":"2019","journal-title":"Diabetes Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01337-7","article-title":"Evaluating the long-term cost-effectiveness of once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes in the UK","volume":"37","author":"Johansen","year":"2020","journal-title":"Adv Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01464-1","article-title":"Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide and sitagliptin in the Spanish setting","volume":"37","author":"Mart\u00edn","year":"2020","journal-title":"Adv Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00915-8","article-title":"A relative cost of control analysis of once-weekly semaglutide versus exenatide extended- release and dulaglutide for bringing patients to HbA1c and weight loss treatment targets in the USA","volume":"36","author":"Johansen","year":"2019","journal-title":"Adv Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1722678","article-title":"Oral semaglutide versus injectable glucagon like peptide-1 receptor agonists: a cost of control analysis","volume":"23","author":"Hansen","year":"2020","journal-title":"J Med Econ"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00736-6","article-title":"Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme","volume":"11","author":"Bain","year":"2020","journal-title":"Diabetes Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01125-y","article-title":"Evaluation of the cost per patient achieving treatment targets with oral semaglutide: a short-term cost-effectiveness analysis in the United States","volume":"36","author":"Hunt","year":"2019","journal-title":"Adv Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13731","article-title":"Switching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance","volume":"75","author":"Jain","year":"2021","journal-title":"Int J Clin Pract"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.645617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T09:35:17Z","timestamp":1672565717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.645617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":65,"alternative-id":["10.3389\/fendo.2021.645617"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.645617","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"article-number":"645617"}}